Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional ‘QoLiTime’ study
Objective: To examine health-related quality of life (QoL) in men with metastatic castration-resistant prostate cancer (mCRPC) on cabazitaxel. Patients and Methods: Men with mCRPC receiving cabazitaxel (25 mg/m², every 3 weeks) and 10 mg/day oral prednis(ol)one were enrolled (2011-2014) in the non-i...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2017
|
| In: |
BJU international
Year: 2016, Volume: 119, Issue: 5, Pages: 731-740 |
| ISSN: | 1464-410X |
| DOI: | 10.1111/bju.13658 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1111/bju.13658 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bju.13658 
|
| Author Notes: | Ralf-Dieter Hofheinz, Carsten Lange, Thorsten Ecke, Susanne Kloss, Burkhard Linsse, Christine Windemuth‐Kieselbach, Peter Hammerer, Salah-Eddin Al‐Batran |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 157854369X | ||
| 003 | DE-627 | ||
| 005 | 20220814215624.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180814r20172016xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bju.13658 |2 doi | |
| 035 | |a (DE-627)157854369X | ||
| 035 | |a (DE-576)50854369X | ||
| 035 | |a (DE-599)BSZ50854369X | ||
| 035 | |a (OCoLC)1341016775 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 245 | 1 | 0 | |a Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel |b the non-interventional ‘QoLiTime’ study |c Ralf-Dieter Hofheinz, Carsten Lange, Thorsten Ecke, Susanne Kloss, Burkhard Linsse, Christine Windemuth‐Kieselbach, Peter Hammerer, Salah-Eddin Al‐Batran |
| 264 | 1 | |c 2017 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First published: 12 September 2016 | ||
| 500 | |a Gesehen am 14.08.2018 | ||
| 520 | |a Objective: To examine health-related quality of life (QoL) in men with metastatic castration-resistant prostate cancer (mCRPC) on cabazitaxel. Patients and Methods: Men with mCRPC receiving cabazitaxel (25 mg/m², every 3 weeks) and 10 mg/day oral prednis(ol)one were enrolled (2011-2014) in the non-interventional prospective ‘QoLiTime’ study. Primary outcome was change in QoL (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item) with respect to prostate-specific antigen (PSA) response after four cycles of cabazitaxel. Secondary outcomes included occurrence of adverse events (AEs). Results: Of 527 men, 348 received four cycles of cabazitaxel and 266 had the necessary PSA level measurements. After four cycles, 92 (34.6%) men had a PSA level decrease ≥50% (responders). QoL remained stable throughout the study (P = 0.62). Change in QoL did not differ between responders and non-responders (P = 0.69). Change in PSA level and global health status between baseline and four cycles showed an inversely proportional relationship (correlation coefficient -0.14; 95% confidence interval -0.26 to -0.01; P = 0.03), with increasing PSA level corresponding to lower health status. Responders showed no change in physical functioning vs baseline (-1.75, P = 0.12); non-responders showed a reduction vs baseline (-7.00, P < 0.001) and responders (P = 0.05). Responders showed an improvement in pain vs baseline (-7.61, P = 0.05) and vs non-responders (P = 0.01). AEs occurred in 292 patients (55.4%), most commonly anaemia (16.5%), fatigue (12.3%) and diarrhoea (11.8%). Neutropenia and febrile neutropenia were reported in 3.8% and 3.6% of patients, respectively. Conclusion: Prostate-specific antigen level response was associated with stable physical functioning and improvement in pain. Symptom increases were seen in areas typical of chemotoxicity, but QoL was maintained. | ||
| 534 | |c 2016 | ||
| 650 | 4 | |a cabazitaxel | |
| 650 | 4 | |a metastatic castration-resistant prostate cancer | |
| 650 | 4 | |a prostate-specific antigen | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a survival | |
| 773 | 0 | 8 | |i Enthalten in |t BJU international |d Oxford : Wiley-Blackwell, 1999 |g 119(2017), 5, Seite 731-740 |h Online-Ressource |w (DE-627)320599426 |w (DE-600)2019983-1 |w (DE-576)091140862 |x 1464-410X |7 nnas |a Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel the non-interventional ‘QoLiTime’ study |
| 773 | 1 | 8 | |g volume:119 |g year:2017 |g number:5 |g pages:731-740 |g extent:10 |a Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel the non-interventional ‘QoLiTime’ study |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bju.13658 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/bju.13658 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180814 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 65500 |e 60000PH121917517 |e 65500PH121917517 |k 0/60000/ |k 1/60000/65500/ |p 1 |x j | ||
| 999 | |a KXP-PPN157854369X |e 3020836905 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Hofheinz","display":"Hofheinz, Ralf-Dieter","given":"Ralf-Dieter","role":"aut"}],"name":{"displayForm":["Ralf-Dieter Hofheinz, Carsten Lange, Thorsten Ecke, Susanne Kloss, Burkhard Linsse, Christine Windemuth‐Kieselbach, Peter Hammerer, Salah-Eddin Al‐Batran"]},"physDesc":[{"extent":"10 S."}],"id":{"eki":["157854369X"],"doi":["10.1111/bju.13658"]},"note":["First published: 12 September 2016","Gesehen am 14.08.2018"],"relHost":[{"pubHistory":["83.1999 -"],"title":[{"title_sort":"BJU international","title":"BJU international","subtitle":"the journal of the British Association of Urological Surgeons, the European Society of Paediatric Urology and the Societé Internationale d'Urologie"}],"part":{"extent":"10","pages":"731-740","issue":"5","volume":"119","year":"2017","text":"119(2017), 5, Seite 731-740"},"language":["eng"],"id":{"eki":["320599426"],"doi":["10.1111/(ISSN)1464-410X"],"issn":["1464-410X"],"zdb":["2019983-1"]},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel the non-interventional ‘QoLiTime’ studyBJU international","note":["Gesehen am 14.03.25"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisherPlace":"Oxford ; Oxford ; Oxford [u.a.]","dateIssuedKey":"1999","publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell","dateIssuedDisp":"1999-"}],"recId":"320599426"}],"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"2017"}],"recId":"157854369X","type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title_sort":"Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel","subtitle":"the non-interventional ‘QoLiTime’ study","title":"Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel"}],"language":["eng"]} | ||
| SRT | |a HOFHEINZRAQUALITYOFL2017 | ||